Payment overview · 2025
General Payments
$1,446.38
75 reported records · 12 companies
Healthcare provider profile · identity verified
Thomas Edward Smallwood, M.D.,CMD
Allopathic & Osteopathic Physicians|Internal Medicine · TOLEDO, OH · NPI 1386644938
Verified facts
What the public records show
CMS Open Payments records show Thomas Edward Smallwood, M.D.,CMD received $1,446.38 in general payments during 2025 across 75 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $317.93 | 22.0% | 19 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $268.77 | 18.6% | 18 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $187.11 | 12.9% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $163.41 | 11.3% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $121.05 | 8.4% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $114.29 | 7.9% | 6 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $71.96 | 5.0% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $70.70 | 4.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.75 | 3.6% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $42.50 | 2.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.96 | 1.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.95 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,403.88 | 74 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $317.93 | 19 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $268.77 | 18 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $187.11 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $163.41 | 5 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $121.05 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $114.29 | 6 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $71.96 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $70.70 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.91 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $44.73 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $44.73 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $42.50 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.19 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.19 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 157 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 116 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
157 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 13 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 996 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 787 | 176 |
| Gabapentin | Gabapentin | 648 | 111 |
| Eliquis | Apixaban | 575 | 62 |
| Furosemide | Furosemide | 529 | 100 |
| Metoprolol Tartrate | Metoprolol Tartrate | 507 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 430 | 89 |
| Lisinopril | Lisinopril | 410 | 84 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 372 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 367 | 68 |
| Metformin Hcl | Metformin Hcl | 347 | 76 |
| Trazodone Hcl | Trazodone Hcl | 344 | 59 |
| Omeprazole | Omeprazole | 331 | 82 |
| Sertraline Hcl | Sertraline Hcl | 312 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 289 | 68 |
| Potassium Chloride | Potassium Chloride | 273 | 61 |
| Tizanidine Hcl | Tizanidine Hcl | 265 | 57 |
| Buspirone Hcl | Buspirone Hcl | 248 | 39 |
| Carvedilol | Carvedilol | 248 | 62 |
| Losartan Potassium | Losartan Potassium | 245 | 58 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 244 | 40 |
| Alprazolam | Alprazolam | 242 | 45 |
| Mirtazapine | Mirtazapine | 242 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 241 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 227 | 53 |
| Divalproex Sodium | Divalproex Sodium | 208 | 23 |
| Famotidine | Famotidine | 200 | 42 |
| Januvia | Sitagliptin Phosphate | 195 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 188 | 64 |
| Donepezil Hcl | Donepezil Hcl | 175 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 165 | 30 |
| Levetiracetam | Levetiracetam | 164 | 25 |
| Simvastatin | Simvastatin | 162 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 43 |
| Farxiga | Dapagliflozin Propanediol | 157 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 156 | 22 |
| Spironolactone | Spironolactone | 151 | 35 |
| Allopurinol | Allopurinol | 147 | 36 |
| Baclofen | Baclofen | 147 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 29 |
| Xarelto | Rivaroxaban | 132 | 15 |
| Pregabalin | Pregabalin | 128 | 24 |
| Risperidone | Risperidone | 124 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 119 | 15 |
| Jardiance | Empagliflozin | 116 | 20 |
| Ibuprofen | Ibuprofen | 114 | 42 |
| Lorazepam | Lorazepam | 111 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 23 |
| Tramadol Hcl | Tramadol Hcl | 108 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 98 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 97 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 22 |
| Meloxicam | Meloxicam | 94 | 22 |
| Montelukast Sodium | Montelukast Sodium | 94 | 16 |
| Olanzapine | Olanzapine | 93 | 13 |
| Topiramate | Topiramate | 93 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 26 |
| Myrbetriq | Mirabegron | 90 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 26 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 87 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 87 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 26 |
| Memantine Hcl | Memantine Hcl | 83 | 12 |
| Metformin Hcl Er | Metformin Hcl | 83 | 18 |
| Prednisone | Prednisone | 83 | 53 |
| Alendronate Sodium | Alendronate Sodium | 79 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 77 | 17 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 76 | suppressed |
| Bumetanide | Bumetanide | 75 | 17 |
| Ozempic | Semaglutide | 73 | 13 |
| Austedo | Deutetrabenazine | 71 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 71 | 22 |
| Azithromycin | Azithromycin | 67 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 63 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 25 |
| Nystatin | Nystatin | 62 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 61 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 16 |
| Colchicine | Colchicine | 60 | 13 |
| Clonidine Hcl | Clonidine Hcl | 59 | 12 |
| Atenolol | Atenolol | 58 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 16 |
| Midodrine Hcl | Midodrine Hcl | 58 | 17 |
| Fluconazole | Fluconazole | 57 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 42 |
| Meclizine Hcl | Meclizine Hcl | 54 | 18 |
| Trulicity | Dulaglutide | 54 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 53 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 52 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 52 | suppressed |
| Bupropion Xl | Bupropion Hcl | 52 | 14 |
| Nifedipine Er | Nifedipine | 52 | 17 |
| Glimepiride | Glimepiride | 50 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 11 |
| Aripiprazole | Aripiprazole | 49 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 15 |
| Entresto | Sacubitril/Valsartan | 47 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 13 |
| Methocarbamol | Methocarbamol | 47 | suppressed |
| Oxycontin | Oxycodone Hcl | 46 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Cephalexin | Cephalexin | 44 | 27 |
| Latanoprost | Latanoprost | 44 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 44 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 43 | suppressed |
| Diazepam | Diazepam | 41 | suppressed |
| Paliperidone Er | Paliperidone | 41 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 31 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 41 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 40 | suppressed |
| Estradiol | Estradiol | 40 | suppressed |
| Finasteride | Finasteride | 39 | 13 |
| Novolog Flexpen | Insulin Aspart | 39 | 14 |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Nitroglycerin | Nitroglycerin | 38 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 37 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 37 | suppressed |
| Movantik | Naloxegol Oxalate | 35 | suppressed |
| Nystop | Nystatin | 35 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | 12 |
| Brilinta | Ticagrelor | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Fetzima | Levomilnacipran Hcl | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 31 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | 12 |
| Insulin Lispro | Insulin Lispro | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 26 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 20 |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 19 |
| Clonazepam | Clonazepam | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 11 |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 21 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Nyamyc | Nystatin | 19 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 18 | 11 |
| Calcium Acetate | Calcium Acetate | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 15 |
| Novolog | Insulin Aspart | 18 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 18 | suppressed |
| Admelog Solostar | Insulin Lispro | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Atazanavir Sulfate | Atazanavir Sulfate | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Ritonavir | Ritonavir | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Glucagon Emergency Kit | Glucagon | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,446.38 · 75 records | Teva Pharmaceuticals USA, Inc. | AFREZZA, AIRSUPRA, AUSTEDO XR, BREZTRI, CAPLYTA, Cologuard Collection Kit, FANAPT, FARXIGA, FREESTYLE LIBRE 3, INGREZZA, JARDIANCE, Korlym, MOUNJARO, Ozempic, Rybelsus, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error